DDInter1024 DDInter927
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lapatinib {u} (Compound) treats {v} (Disease) breast cancer
Lapatinib {u} (Compound) binds {v} (Gene) TAP1
Lapatinib {u} (Compound) upregulates {v} (Gene) VAV3
Lapatinib {u} (Compound) downregulates {v} (Gene) PLOD3
Lapatinib {u} (Compound) causes {v} (Side Effect) Nail disorder
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propofol
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lapatinib (Compound) treats breast cancer (Disease)
Lapatinib (Compound) binds TAP1 (Gene)
Lapatinib (Compound) upregulates VAV3 (Gene)
Lapatinib (Compound) downregulates PLOD3 (Gene)
Lapatinib (Compound) causes Nail disorder (Side Effect)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin